Targeting NCCA-ATP channel for organ protection following ischemic episode
US-9511075-B2 · Dec 6, 2016 · US
Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US8980952B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980952-B2 |
| Application number | US-35994606-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2006 |
| Priority date | Mar 20, 2002 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NC Ca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NC Ca-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NC Ca-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NC Ca-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of ameliorating the effect of a reduction in blood flow in peri-infarct brain tissue in ischemic disease or injury in a subject comprising administering to a subject having a reduction in blood flow in peri-infarct brain tissue in ischemic disease or injury an amount of a compound that is effective to inhibit the activity of a NC Ca-ATP channel in a neuronal cell, a neuroglia cell, or a neural endothelial cell and that is effective to ameliorate the…
Assignees
Inventors
Classifications
Operations & Transport · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980952B2 cover?
- The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NC Ca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NC Ca-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited …
- Who is the assignee on this patent?
- Simard J Marc, Chen Mingkui, Univ Maryland, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/64. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).